Guilford company targeting 'unprecedented demand' with its at-home COVID test
Detect’s COVID-19 Test is undergoing U.S. Food and Drug Administration review.
Stay updated with breaking news from Rapid Acceleration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Detect’s COVID-19 Test is undergoing U.S. Food and Drug Administration review.
Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).
/PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B...
Biomarkers detected in saliva samples could be potential indicators of disease severity in children with COVID, new research shows.
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.